Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
- Associated Therapies
- -
Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 744
- Registration Number
- NCT00002868
- Locations
- 🇬🇧
Royal Infirmary, Glasgow, Scotland, United Kingdom
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Riverview Medical Center - Booker Cancer Center, Red Bank, New Jersey, United States
Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2012-07-16
- Target Recruit Count
- 31
- Registration Number
- NCT00077116
- Locations
- 🇨🇭
Universitaetsspital-Basel, Basel, Switzerland
🇧🇪AZ Sint-Jan, Brugge, Belgium
🇧🇪H. Hartziekenhuis - Roeselaere., Roeselare, Belgium
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML
- Conditions
- Interventions
- First Posted Date
- 2003-12-23
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Eleos, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT00074737
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸University of Miami Health Center, Miami, Florida, United States
🇺🇸North Shore University Hospital, Lake Success, New York, United States
Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2003-12-10
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 13
- Registration Number
- NCT00003729
- Locations
- 🇧🇪
Academisch Ziekenhuis der Vrije Universiteit Brussel, Brussels (Bruxelles), Belgium
🇧🇪U.Z. Gasthuisberg, Leuven, Belgium
🇧🇪Universitair Ziekenhuis Gent, Ghent (Gent), Belgium
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
- First Posted Date
- 2003-11-25
- Last Posted Date
- 2009-02-09
- Target Recruit Count
- 207
- Registration Number
- NCT00002989
- Locations
- 🇮🇹
Ospedale San Eugenio, Rome, Italy
🇧🇪Institut Jules Bordet, Brussels (Bruxelles), Belgium
🇩🇪Eberhard Karls Universitaet, Tuebingen, Germany
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2003-11-24
- Last Posted Date
- 2012-11-19
- Lead Sponsor
- Columbia University
- Registration Number
- NCT00002761
Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-11-24
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 2078
- Registration Number
- NCT00002812
- Locations
- 🇺🇸
Children's Hospital of Columbus, Columbus, Ohio, United States
🇺🇸Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis
- Conditions
- First Posted Date
- 2003-11-11
- Last Posted Date
- 2010-06-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00006367
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸University of Illinois College of Medicine, Chicago, Illinois, United States
High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2003-04-16
- Last Posted Date
- 2012-04-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 61
- Registration Number
- NCT00002945
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Combination Chemotherapy in Treating Patients With Lymphoma
- Conditions
- Interventions
- Biological: Filgrastim (G-CSF)Biological: Bleomycin Sulfate (BLM)Biological: Recombinant Interferon AlfaDrug: CarmustineDrug: Cytarabine (ARA-C)Drug: Cisplatin (CDDP)Drug: Etoposide (VP-16)Drug: CyclophosphamideDrug: IfosfamideDrug: IdarubicinDrug: MelphalanDrug: Leucovorin CalciumDrug: mitoxantrone hydrochloride (DHAD)Drug: MethotrexateProcedure: Peripheral Blood Stem Cell TransplantationDrug: MethylprednisoloneDrug: Vincristine SulfateRadiation: Radiation Therapy
- First Posted Date
- 2003-04-16
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 116
- Registration Number
- NCT00002835
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.